Clinical Trial Update: Bioequivalence Study of Metformin Hydrochloride Extended-Release Tablets USP 750 mg Under Fed Condition [Phase 1]

View source ↗

Summary

A Phase 1 bioequivalence study of Metformin hydrochloride extended-release tablets USP 750 mg under fed condition has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Metformin Hydrochloride Extended-Release Tablets USP 750 mg (metformin hydrochloride extended-release)

Snippet

Sponsor: IPCA Laboratories Ltd. | Conditions: Fasting | Phase 1 | Status: COMPLETED